AI Startup Snags $50 Million to Speed Up Clinical Research
- Unlearn.ai makes virtual copies of clinical-trial participants
- Its tech could make clinical trials faster, less expensive
This article is for subscribers only.
Unlearn.ai, an artificial intelligence startup that helps speed up clinical research, raised $50 million from investors led by Altimeter Capital Management to fund its push to upend drug development.
The San Francisco-based startup will use the capital to expand its team and boost engineering and R&D capabilities. Backers in the Series C round include Radical Ventures, Mubadala Capital and Wittington Ventures and others, the startup said on Thursday.